Knockdown of HSD17B13 mRNA, Pharmacokinetics, Safety, and Tolerability, of AZD7503 in Non-Alcoholic Fatty Liver Disease

Study identifier:D9230C00003

ClinicalTrials.gov identifier:NCT05560607

EudraCT identifier:N/A

CTIS identifier:N/A

Recruiting

Official Title

An Open-label, Non-randomized, Multiple-dose Study to Assess the Knockdown of Hepatic HSD17B13 mRNA Expression, Pharmacokinetics, Safety, and Tolerability Following Administration of AZD7503 in Participants with Non-alcoholic Fatty Liver Disease

Medical condition

non-alcoholic fatty liver disease

Phase

Phase 1

Healthy volunteers

No

Study drug

-

Sex

All

Estimated Enrollment

20

Study type

Interventional

Age

18 Years - 70 Years

Date

Study Start Date: 12 Aug 2022
Estimated Primary Completion Date: 21 Dec 2023
Estimated Study Completion Date: 21 Dec 2023

Study design

Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Other

Verification:

Verified 01 Aug 2023 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria